Anti-Biotin - 30nm Gold Conjugate
Cytodiagnostics
SKU:AC-30-22-05
Couldn't load pickup availability

Anti-Biotin - 30nm Gold Conjugate for gold nanoparticle labelling
Anti-Biotin - 30nm Gold Conjugate gives assay developers a defined route to detect biotin-labelled targets across Lateral Flow Assay, Immunoblotting and Electron Microscopy. It helps researchers evaluate target fit, assay readout and control strategy before selecting a related label or antibody format.
Assay context
The colloidal gold label provides a permanent, electron-dense and optically visible signal for method development and routine detection workflows. This mid-sized gold particle is a practical choice when both particle visibility and access to the labelled target must be balanced.
Experimental considerations
- Fits workflows that require clear Biotin detection and a reagent choice that can be documented consistently.
- Useful during assay development when conjugate signal, membrane migration and background must be tuned together.
- Include matched negative controls and optimize blocking to separate true target-associated signal from nonspecific particle binding.
Reference AC-30-22-05 in protocols, purchasing notes and internal reagent libraries when matching this product to your chosen assay. For protocol transfer, record the catalog reference together with the selected application and control strategy.
- Research Area:
- Immunology • Nanotechnology & Biosensors • Assay Development
- Application:
- Lateral Flow Assay • Immunoblotting • Electron Microscopy
- Reactivity:
- Biotin
- Host:
- Goat
- Clonality:
- Polyclonal
- Isotype:
- IgG
- Formulation:
- 20mM Tris (pH 8.0), 150mM NaCl, 20% glycerol (v/v), 1% BSA
- Adsorption Max:
- 526nm
- Core Size:
- 30nm
- Shape:
- Spherical
- Material:
- Gold
- Storage Temperature:
- 4°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.